THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, May 22, 2023
Pharma services are becoming increasingly important due to patient-centricity, regulatory requirements, and technological advancements, creating an opportunity for growth.
The demand for outsourced pharmaceutical services is still robust, although the border market is facing challenges and the M&A market is relatively weak. The current focus is on large molecule speciality drugs, precision medicines, and evidence-based, value-based, and patient-centred healthcare is contributing to this trend.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The pharma service has continued momentum around large molecules of speciality drugs, the expansion of precision medicine pathways, and macro forces driving evidence-based, value-based, and patient-centric healthcare. This trend is continuing with the ongoing M&A activity in the sector. Based on the recent market activity and interactions with pharma services companies and healthcare investors several key trends have emerged, which are growing the market's attention.
The Expanding Role of Artificial Intelligence Across the Value Chain
To accelerate drug development, lower failure rates, and reduce associated costs, clinical trial sponsors are eager to shorten the time it takes to bring new therapies and devices to market. For instance, a new approach that integrates high-quality, diverse data into AI models across drug discovery. From molecular design to chemical synthesis and new therapeutic targeting.
Focus on Clinical Trial Optimisation
Pharmaceutical and biotech industries are carefully selecting which drugs and indications to develop and commercialise and can evaluate the tradeoff among speed to market, trial cost, and the likelihood of therapeutic success. To optimise the research sites, are using optimisation solutions that are enabling more intelligent and efficient clinical trials.
The site optimisation allows communities to providers to showcase their unique attributes, like physician expertise, patient population demographics, and past performance. The diversity and geographic accessibility increase, by allowing community providers to participate in trials that best fit them. There is a significant demand for outsourced commercialisation services. This trend has continued in the present year, with a focus on platform acquisition. Companies with established expertise and infrastructure are investing in improving speciality patients' access to therapy and adherence while enhancing affordability.
As healthcare becomes more patient-centred, personalised, and value-based, outsourced pharma services are becoming increasingly important. As a result, there is a significant opportunity to disrupt the traditional approach to drug development and commercialisation. Top buyers, including both strategic and private equity players, are showing sustained interest in pharma services. Private equity investors see it as a diversified opportunity to benefit from growth in the underlying pharma and biotech sectors, while strategic platforms see it as an opportunity for competitive differentiation, market expansion, and new market entry. Consolidation is expected to continue, even as innovative point solutions emerge within an ecosystem of few scaled, multi-dimensional platforms.
The outsourcing of pharma services is becoming increasingly important as the healthcare industry becomes more patient-centric, personalised, and value-based. This, coupled with regulatory requirements and technological advancements, creates an opportunity to disrupt traditional drug development and commercialisation. Private equity firms and strategic platforms continue to show interest in pharma services as it provides a diversified opportunity for growth in the underlying pharma and biotech sectors. Consolidation is expected to continue as few scaled, multi-dimensional platforms emerge.
More in News